Search
Lurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigational[A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression … [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials
Products: ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIALAzaperone
go.drugbank.com/drugs/DB11376InvestigationalVet approvedMore rarely it may be used in humans as an antipsychotic drug, but this is uncommon.
Categories: Dopamine D2 Receptor AntagonistsProducts: AZANIL 40MG/ML INJECTIONRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions.
Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis.
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-Brimapitide
go.drugbank.com/drugs/DB15231InvestigationalBrimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Dexbrompheniramine
go.drugbank.com/drugs/DB00405ApprovedDexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Mixtures: M-end Max D, M-end DmxSynonyms: d-brompheniramine, 3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-aminePulmonary Tuberculosis resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug
go.drugbank.com/conditions/DBCOND0154352Drugs: PretomanidSynonyms: Pulmonary Tuberculosis resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drugCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigational[A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L23524] In November 2021, the same indication was approved by the EMA.
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigational[A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. … US in December 2021.
PRTX-100
go.drugbank.com/drugs/DB05947InvestigationalPRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases
Synonyms: PRTX 100